GLP-1 medicines may cut clot-related risks in chronically inflamed patients

https://www.news-medical.net/news/20260610/GLP-1-medicines-may-cut-clot-related-risks-in-chronically-inflamed-patients.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A large real-world analysis suggests GLP-1 receptor agonists may offer clot-related and survival benefits in a chronically inflamed, high-risk population, while leaving some cardiovascular endpoints unchanged. In a recent study published in the Journal of the American Heart Association, researchers emulated a target trial to assess the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment and the risk of thromboembolic and cardiovascular events in adults with obesity and comorbid autoimmune disease (AID).